Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

Prior treatment

• Patients who received percutaneous coronary intervention
• Patients who are receiving hemodialysis or peritoneal dialysis or received renal transplantation due to end-stage renal failure

Other illness

• Patients diagnosed with acute coronary artery diseases (STEMI, NSTEMI, Unstable angina)
• Patients who have been diagnosed with stroke, transitory ischemic attack, and peripheral artery diseases.
• Patients diagnosed with variant myocardial infarction
• Patients with severe liver diseases or lung diseases and/or malignant tumor with life expectancy of less than 3 years
• Patients with severe valvular heart disease

Other

• Patients with an intermediate (\>30%) lesion on the left main coronary artery.
• Patients who are hypersensitive or prohibited from using the active substance (Ezetimibe or Rosuvastatin) of the study medicines
• Patients with cardiogenic shock
• Pregnant women or women who are planning to get pregnant
• Patients who participated in other clinical studies within the past three months (except for non-interventional observation studies)

• Male and female adjusts (19 or older)
• Patients with suspected stable angina pectoris without coronary artery interventions, who showed a minimal to intermediate coronary artery diseases (a stenosis of 10 to 70% diameter as per QCA) in at least one natural coronary artery in coronary artery angiography or coronary artery CT.
• Patients who gave their informed consent themselves in writing.
• Patients who were treated with statin or lipid-lowering agents may participate in the study by changing the existing medicines.